Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00347165
Status:
TERMINATED
Last Update Posted:
2024-05-30
First Post:
2006-06-29
Brief Title:
Intravitreal Bevacizumab for Age-Related Macular Degeneration
Sponsor:
Asociación para Evitar la Ceguera en México
Organization:
Asociación para Evitar la Ceguera en México
Study Overview
Official Title:
Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration A Pilot Study
Status:
TERMINATED
Status Verified Date:
2024-05
Last Known Status:
Recruiting
Delayed Posting:
No
If Stopped, Why?:
undefined
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
Detailed Description:
The neovascular age related macular degenerationAMD is a important cause of legal blindness in adults older than 50 years Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy Bevacizumab has been reported effective used as intravenous injection for AMD But serious side effects have been reported with the use of this drug in oncologic patients The intravitreal use has been reported in limited case reports and safety and efficacy should be determined
The purpose of this study is efficacy and safety of 25 mg intravitreal of bevacizumab for AMD
The purpose of this study is efficacy and safety of 25 mg intravitreal of bevacizumab for AMD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None